A Phase 2 interventional study of Varenicline and Placebo in Alzheimer's Disease, sponsored by Pfizer. Completed at 8 sites in Korea, Republic of. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-11-22.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Alzheimer Disease by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Pfizer.
Among the 101 studies in Alzheimer Disease by Pfizer, this one is the 41st largest by enrollment of the 94 interventional ones that give a count, is one of 31 that started in 2009, is one of 24 in phase 2, and was the 47th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →1 of the 101 studies in Alzheimer Disease by Pfizer is open now. Recruiting first, the newest first:
Pfizer
Ages 18–85 · Healthy volunteers
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 27 · Phase 3 17
First in 1999; this study’s year is marked. 31 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 56 across the 94 interventional studies, 370 across the 5 observational. Of the 99 that completed or were terminated, 40 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Alzheimer Disease by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07897708PfizerA Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults | 2027-03-17 |
Add it to your calendar (.ics) → With an account.
Among the 101 studies in Alzheimer Disease by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Varenicline
Drug: Placebo
0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
Also known as: Chantix, Champix
Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6
12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.
Time frame: Week 6
Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3
12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.
Time frame: Week 3
Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3
11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.
Time frame: Week 3
Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6
11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.
Time frame: Week 6
Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.
Time frame: Week 6
Neuropsychiatric Inventory (NPI) Total Score at Week 3
Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.
Time frame: Week 3
Neuropsychiatric Inventory (NPI) Total Score at Week 6
Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.
Time frame: Week 6
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1
Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 1
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3
Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 3
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6
Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 6
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1
Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.
Time frame: Week 1
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3
Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.
Time frame: Week 3
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6
Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.
Time frame: Week 6
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1
Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 1
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3
Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 3
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6
Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 6
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1
Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 1
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3
Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 3
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6
Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
Time frame: Week 6
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1
Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 1
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3
Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 3
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6
Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
Time frame: Week 6
| Milestone | Varenicline Then Placebo | Placebo Then Varenicline |
|---|---|---|
| Started | 32 | 34 |
| Treated | 31 | 33 |
| Completed | 26 | 29 |
| Not completed | 6 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Other | 0 | 2 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Randomized but not treated | 1 | 1 |
| Milestone | Varenicline Then Placebo | Placebo Then Varenicline |
|---|---|---|
| Started | 26 | 29 |
| Completed | 26 | 29 |
| Not completed | 0 | 0 |
| Milestone | Varenicline Then Placebo | Placebo Then Varenicline |
|---|---|---|
| Started | 26 | 29 |
| Completed | 26 | 28 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.
| units on scale | Varenicline | Placebo |
|---|---|---|
| Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6 | 18.07 ± 0.942 | 18.49 ± 0.939 |
12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.
| units on scale | Varenicline | Placebo |
|---|---|---|
| Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3 | 19.87 ± 0.935 | 19.31 ± 0.941 |
11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.
| units on scale | Varenicline | Placebo |
|---|---|---|
| Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3 | 19.60 ± 0.880 | 19.01 ± 0.885 |
11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.
| units on scale | Varenicline | Placebo |
|---|---|---|
| Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6 | 17.86 ± 0.886 | 18.23 ± 0.884 |
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.
| units on a scale | Varenicline | Placebo |
|---|---|---|
| Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6 | 3.71 ± 0.103 | 3.70 ± 0.102 |
Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.
| scores on scale | Varenicline | Placebo |
|---|---|---|
| Neuropsychiatric Inventory (NPI) Total Score at Week 3 | 2.97 ± 0.845 | 2.29 ± 0.858 |
Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.
| scores on scale | Varenicline | Placebo |
|---|---|---|
| Neuropsychiatric Inventory (NPI) Total Score at Week 6 | 3.82 ± 0.857 | 2.55 ± 0.855 |
Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
| log10 millisecond | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1 | 2.65 ± 0.015 | 2.64 ± 0.015 |
Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
| log10 millisecond | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3 | 2.65 ± 0.015 | 2.63 ± 0.015 |
Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
| log10 millisecond | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6 | 2.64 ± 0.015 | 2.65 ± 0.015 |
Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.
| errors | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1 | 38.52 ± 2.586 | 40.05 ± 2.626 |
Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.
| errors | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3 | 39.43 ± 2.600 | 43.57 ± 2.656 |
Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.
| errors | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6 | 41.67 ± 2.668 | 42.98 ± 2.641 |
Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
| arcsine proportion correct | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1 | 0.94 ± 0.031 | 0.94 ± 0.031 |
Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
| arcsine proportion correct | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3 | 0.96 ± 0.031 | 0.97 ± 0.032 |
Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
| arcsine proportion correct | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6 | 0.95 ± 0.032 | 0.96 ± 0.031 |
Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
| arcsine proportion correct | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1 | 0.83 ± 0.015 | 0.81 ± 0.016 |
Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
| arcsine proportion correct | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3 | 0.82 ± 0.016 | 0.82 ± 0.016 |
Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.
| arcsine proportion correct | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6 | 0.83 ± 0.016 | 0.84 ± 0.016 |
Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
| log10 millisecond | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1 | 2.79 ± 0.011 | 2.80 ± 0.011 |
Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
| log10 millisecond | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3 | 2.79 ± 0.011 | 2.80 ± 0.011 |
Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.
| log10 millisecond | Varenicline | Placebo |
|---|---|---|
| Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6 | 2.79 ± 0.012 | 2.79 ± 0.011 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline | — | 2/60 (3.3%) | 56/60 (93.3%) |
| Placebo | — | 0/59 (0%) | 37/59 (62.7%) |
| Event | Varenicline | Placebo |
|---|---|---|
| AstheniaGeneral disorders | 1/60 | 0/59 |
| FractureInjury, poisoning and procedural complications | 1/60 | 0/59 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/60 | 0/59 |
| Event | Varenicline | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 17/60 | 2/59 |
| Decreased appetiteMetabolism and nutrition disorders | 13/60 | 6/59 |
| VomitingGastrointestinal disorders | 12/60 | 0/59 |
| DizzinessNervous system disorders | 8/60 | 0/59 |
| HeadacheNervous system disorders | 7/60 | 4/59 |
| NasopharyngitisInfections and infestations | 2/60 | 4/59 |
| DyspepsiaGastrointestinal disorders | 4/60 | 1/59 |
| ConstipationGastrointestinal disorders | 3/60 | 2/59 |
| Abdominal pain upperGastrointestinal disorders | 2/60 | 2/59 |
| Urinary tract infectionInfections and infestations | 2/60 | 2/59 |
| Age Continuous(years) | Varenicline Then Placebo | Placebo Then Varenicline | Total |
|---|---|---|---|
| Mean | 71.5 ± 8.7 | 73.9 ± 5.8 | 72.7 ± 7.4 |
| Sex: Female, Male(Participants) | Varenicline Then Placebo | Placebo Then Varenicline | Total |
|---|---|---|---|
| Female | 21 | 21 | 42 |
| Male | 11 | 13 | 24 |
The record gives a start of Jul 2009, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline